Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-CRC: Immunotherapy Combinations in Metastatic Colorectal Cancer
NCT03555149Phase 2Terminated
- Sponsor
- Roche
- Start
- Sep 2018
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of atezolizumab in metastatic colorectal cancer (mCRC), sponsored by Roche. Started Sep 2018; status: terminated.
02
Drugs
atezolizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03555149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03555149.